{"id":51135,"date":"2018-09-11T03:52:44","date_gmt":"2018-09-11T07:52:44","guid":{"rendered":"http:\/\/utnews.utoledo.edu\/?p=51135"},"modified":"2018-09-10T14:25:17","modified_gmt":"2018-09-10T18:25:17","slug":"ut-chemists-awarded-2-1-million-to-develop-new-antibiotic-to-treat-tb","status":"publish","type":"post","link":"https:\/\/news.utoledo.edu\/index.php\/09_11_2018\/ut-chemists-awarded-2-1-million-to-develop-new-antibiotic-to-treat-tb","title":{"rendered":"UT chemists awarded $2.1 million to develop new antibiotic to treat TB"},"content":{"rendered":"<p>The National Institutes of Health awarded a team of chemists at The University of Toledo a five-year, $2.1 million grant to create a new, more effective drug to treat tuberculosis, the most common cause of death from an infectious disease worldwide.  <\/p>\n<p>The grant renews funding through 2023 for the project that combats drug resistance to current antibiotics.<\/p>\n<p><div id=\"attachment_51194\" style=\"width: 550px\" class=\"wp-caption alignright\"><a href=\"http:\/\/news.utoledo.edu\/?attachment_id=51194\" rel=\"attachment wp-att-51194\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-51194\" src=\"http:\/\/news.utoledo.edu\/wp-content\/uploads\/2018\/09\/Ronning-and-Sucheck-by-Dan.jpg\" alt=\"\" width=\"540\" height=\"360\" class=\"size-full wp-image-51194\" srcset=\"https:\/\/news.utoledo.edu\/wp-content\/uploads\/2018\/09\/Ronning-and-Sucheck-by-Dan.jpg 540w, https:\/\/news.utoledo.edu\/wp-content\/uploads\/2018\/09\/Ronning-and-Sucheck-by-Dan-300x200.jpg 300w\" sizes=\"(max-width: 540px) 100vw, 540px\" \/><\/a><p id=\"caption-attachment-51194\" class=\"wp-caption-text\">Dr. Donald Ronning, left, and Dr. Steve Sucheck are using a five-year, $2.1 million grant from the National Institutes of Health to develop a better drug to treat tuberculosis.<\/p><\/div>Dr. Donald Ronning and Dr. Steve Sucheck, professors in the UT Department of Chemistry and Biochemistry, will build on their progress made in the fight against Mycobacterium tuberculosis, which can be spread through coughing, sneezing or laughing, and kills more people each year than HIV, malaria and the flu. It takes at least six months to clear the infection with the drugs currently available.<\/p>\n<p>\u201cAntibiotics discovered 60 years ago are becoming obsolete as bacteria naturally evolve to outsmart drug therapies,\u201d Sucheck said. \u201cMycobacterium tuberculosis, which kills 1.5 million people a year, is one of a number of bacteria that have become increasingly drug-resistant.\u201d<\/p>\n<p>\u201cWe\u2019re designing an antibiotic to shorten the time it takes to clear the infection,\u201d Ronning said. \u201cInstead of six to 24 months, we\u2019re aiming for a therapy of two weeks, like treating strep throat or an ear infection, as well as reducing the side effects.\u201d<\/p>\n<p>The team has published several papers about breakthroughs in their ongoing research in journals, including Nature Communications, Scientific Reports and the Journal of Biological Chemistry, as well as the American Chemical Society\u2019s journals Biochemistry and Infectious Diseases.<\/p>\n<p>\u201cWe\u2019ve used X-rays to structurally characterize two targets and are making progress in understanding how to better hit those targets to make a molecule that is going to be much more potent against the bacterium that causes tuberculosis,\u201d Ronning said.<\/p>\n<p>The research centers around inhibiting two essential classes of enzymes found in Mycobacterium tuberculosis. One is called the antigen 85 Complex that the researchers learned changes shape as it performs its job in the cell, making the protein more vulnerable to some of the compounds the lab has been testing. The second enzyme class synthesizes long polymers of sugar. Inhibiting this enzyme promotes an accumulation of compounds toxic to the bacterium and leads to rapid killing.<\/p>\n<p>\u201cThere is a tremendous need to identify new drugs and new drug targets that can be used to treat this increasingly drug-resistant bacteria,\u201d Sucheck said. \u201cWe are creating something that has never been made. The work is urgent because many cases of TB are almost impossible to treat.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Donald Ronning and Dr. Steve Sucheck of the UT Department of Chemistry and Biochemistry are using a five-year, $2.1 million grant from the National Institutes of Health to develop a better drug to treat tuberculosis.<\/p>\n","protected":false},"author":812,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,1,3,7],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/posts\/51135"}],"collection":[{"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/users\/812"}],"replies":[{"embeddable":true,"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/comments?post=51135"}],"version-history":[{"count":3,"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/posts\/51135\/revisions"}],"predecessor-version":[{"id":51195,"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/posts\/51135\/revisions\/51195"}],"wp:attachment":[{"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/media?parent=51135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/categories?post=51135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.utoledo.edu\/index.php\/wp-json\/wp\/v2\/tags?post=51135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}